VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ A positive history of chronic claudication         │ A positive history of chronic claudication         │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Exercise-limiting claudication established by      │ Exercise-limiting claudication established by      │     100 │
│ history and direct observation during a screening  │ history and direct observation during a screening  │         │
│ walking test administered by the evaluating        │ walking test administered by the evaluating        │         │
│ vascular surgeon                                   │ vascular surgeon                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Arterial occlusive disease per ankle Brachial      │ Arterial occlusive disease per ankle Brachial      │     100 │
│ index measurements and/or other imaging modalities │ index measurements and/or other imaging modalities │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Stable blood pressure regimen, stable lipid        │ Stable blood pressure regimen, stable lipid        │     100 │
│ regimen, stable diabetes regimen and risk factor   │ regimen, stable diabetes regimen and risk factor   │         │
│ control for 6 weeks                                │ control for 6 weeks                                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Rest pain or tissue loss due to PAD (Fontaine      │ Rest pain or tissue loss due to PAD (Fontaine      │     100 │
│ stage III and IV)                                  │ stage III and IV)                                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ acute lower extremity ischemic event secondary to  │ acute lower extremity ischemic event secondary to  │     100 │
│ thromboembolic disease or acute trauma             │ thromboembolic disease or acute trauma             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Walking capacity significantly limited by          │ Walking capacity significantly limited by          │     100 │
│ conditions other than claudication including leg   │ conditions other than claudication including leg   │         │
│ (joint/musculoskeletal, neurologic) and systemic   │ (joint/musculoskeletal, neurologic) and systemic   │         │
│ (heart, lung disease) pathology                    │ (heart, lung disease) pathology                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Current use of either ACE inhibitors or            │ Current use of either ACE inhibitors or            │     100 │
│ angiotensin II receptor blockers                   │ angiotensin II receptor blockers                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of bilateral severe renal artery stenosis  │ History of bilateral severe renal artery stenosis  │     100 │
│ and 7) History of angioedema related to previous   │ and 7) History of angioedema related to previous   │         │
│ ACE-inhibitor treatment or known hypersensitivity  │ ACE-inhibitor treatment or known hypersensitivity  │         │
│ to ramipril or other ACE inhibitors                │ to ramipril or other ACE inhibitors                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Chronic kidney disease with estimated Glomerular   │ Chronic kidney disease with estimated Glomerular   │      99 │
│ Filtration Rate \< 30 ml/min/1.73 m2               │ Filtration Rate < 30 ml/min/1.73 m2                │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤════════════════════════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria                              │   Score │
╞═══════════════════════════════════╪════════════════════════════════════════════╪═════════╡
│ Must have maximum age of 90 Years │ A positive history of chronic claudication │      32 │
├───────────────────────────────────┼────────────────────────────────────────────┼─────────┤
│ Must have minimum age of 18 Years │ Current use of either ACE inhibitors or    │      36 │
│                                   │ angiotensin II receptor blockers           │         │
╘═══════════════════════════════════╧════════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 97
Average Levenshtein Ratio of individual lines: 88.91666666666667
OverAll Ratio: 92.95833333333334
